| Literature DB >> 19519524 |
Caroline Brunetto de Farias1, Laura Stertz, Rodrigo Cruz Lima, Flávio Kapczinski, Gilberto Schwartsmann, Rafael Roesler.
Abstract
The gastrin-releasing peptide receptor (GRPR) is a therapeutic target in colon cancer. Here we show that the GRPR antagonist RC-3095 (10(-3), 10(-6), or 1 microM) decreases nerve growth factor (NGF) secretion measured by enzyme-linked immunosorbent assay (ELISA) in HT-29 human colon carcinoma cells. The results suggest that decreased secretion of neurotrophins might be a novel mechanism by which GRPR antagonists exert their antiproliferative effects in cancer cells.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19519524 DOI： 10.2174/092986609788490177
Source DB: PubMed Journal: Protein Pept Lett ISSN： 0929-8665 Impact factor: 1.890